FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study
Authors:
- Emily C DaughertyEDEmily C Daugherty
- Anthony MasciaAMAnthony Mascia
- Yong ZhangYZYong Zhang
- Eunsin LeeELEunsin Lee
- Zhiyan XiaoZXZhiyan Xiao
- Mathieu SertorioMSMathieu Sertorio
- Jennifer WooJWJennifer Woo
- Claire McCannCMClaire McCann
- Kenneth RussellKRKenneth Russell
- Lisa LevineLLLisa Levine
- Ricky SharmaRSRicky Sharma
- Deepak KhuntiaDKDeepak Khuntia
Top Cited Papers
Open Access
- 5 January 2023
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e41812
Abstract
Background: In preclinical studies, FLASH therapy, in which radiation delivered at ultrahigh dose rates of ≥40 Gy per second, has been shown to cause less injury to normal tissues than radiotherapy delivered at conventional dose rates. This paper describes the protocol for the first-in-human clinical investigation of proton FLASH therapy. Objective: FAST-01 is a prospective, single-center trial designed to assess the workflow feasibility, toxicity, and efficacy of FLASH therapy for the treatment of painful bone metastases in the extremities. Methods: Following informed consent, 10 subjects aged ≥18 years with up to 3 painful bone metastases in the extremities (excluding the feet, hands, and wrists) will be enrolled. A treatment field selected from a predefined library of plans with fixed field sizes (from 7.5 cm × 7.5 cm up to 7.5 cm × 20 cm) will be used for treatment. Subjects will receive 8 Gy of radiation in a single fraction—a well-established palliative regimen evaluated in prior investigations using conventional dose rate photon radiotherapy. A FLASH-enabled Varian ProBeam proton therapy unit will be used to deliver treatment to the target volume at a dose rate of ≥40 Gy per second, using the plateau (transmission) portion of the proton beam. After treatment, subjects will be assessed for pain response as well as any adverse effects of FLASH radiation. The primary end points include assessing the workflow feasibility and toxicity of FLASH treatment. The secondary end point is pain response at the treated site(s), as measured by patient-reported pain scores, the use of pain medication, and any flare in bone pain after treatment. The results will be compared to those reported historically for conventional dose rate photon radiotherapy, using the same radiation dose and fractionation. Results: FAST-01 opened to enrollment on November 3, 2020. Initial results are expected to be published in 2022. Conclusions: The results of this investigation will contribute to further developing and optimizing the FLASH-enabled ProBeam proton therapy system workflow. The pain response and toxicity data acquired in our study will provide a greater understanding of FLASH treatment effects on tumor responses and normal tissue toxicities, and they will inform future FLASH trial designs. Trial Registration: : ClinicalTrials.gov NCT04592887; http://clinicaltrials.gov/ct2/show/NCT04592887 International Registered Report Identifier (IRRID): DERR1-10.2196/41812Keywords
This publication has 33 references indexed in Scilit:
- Cancer to bone: a fatal attractionNature Reviews Cancer, 2011
- Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based GuidelineInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Apparent absence of a proton beam dose rate effect and possible differences in RBE between Bragg peak and plateauMedical Physics, 2010
- No Evidence for a Different RBE between Pulsed and Continuous 20 MeV ProtonsRadiation Research, 2009
- The Measurement of Pain from Metastatic Bone Disease: Capturing the Patient's ExperienceClinical Cancer Research, 2006
- Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone MetastasesJNCI: Journal of the National Cancer Institute, 2005
- Hyperfast, early cell response to ionizing radiationInternational Journal of Radiation Biology, 2000
- Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiationInternational Journal of Radiation Biology, 2000
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Effects of Dose-rate on the Radiation Response of Rat SkinInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1974